I'll research ACGL (Arch Capital Group) thoroughly before writing the preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent earnings materials (Q1 2026 release and call) and gather stock price data.Now let me gather stock price data and recent market/industry context for Q2 2026.Let me get the year-ago Q2 2025 release for the comparison base and check recent industry/cat context.# Arch Capital Group (ACGL) — Q2 2026 Earnings Preview
Arch heads into its Q2 print as a best-in-class, cycle-managing specialty (re)insurer that is now clearly operating on the back side of the P&C pricing cycle. The story for the last several quarters has shifted from "how fast can Arch grow into a hard market" to "how well can Arch defend margins and redeploy capital as pricing softens." That framing is what matters most on this call.
Stock context: ACGL trades at ~$103.91 (7/27), up roughly 11% YTD from ~$93.86 to start the year, and sits near its 2026 highs after a strong July. Worth noting: the stock sold off ~4.5% the day of its Q1 report (4/29, $97.06 → $92.72) even on a solid quarter — a reminder that with a soft market and elevated expectations, the market is scrutinizing underlying margins and growth, not headline beats. At ~1.6x the Q1 book value per share of $66.19, valuation leaves limited room for disappointment.
Year-ago base (Q2 2025): - Net income: $1.23B / $3.23 per share (22.9% annualized net income ROE) - Operating income: $979M / $2.58 per share (18.2% annualized operating ROE) - Ex-cat, ex-PYD combined ratio: 80.9% - Pre-tax cat losses: $154M; favorable prior-year development: $139M - Book value/share: $59.17; buybacks: only ~$163M
Most recent quarter (Q1 2026): - Operating income: $901M / $2.50 per share (15.4% operating ROE) - Ex-cat, ex-PYD combined ratio: 82.3% (up ~130 bps YoY — the softening signal) - Cat losses: $174M; favorable PYD: $200M (boosted ~25% by a large reinsurance commutation) - Book value/share: $66.19 (+1.7% QoQ) - Buybacks: $783M (8.3M shares) + $311M more early in Q2
The YoY EPS comparison will be tough: Q2 2025 was an unusually strong quarter (18.2% operating ROE, light cats, big realized gains). Expect optics of a YoY decline that is more about a hard comp and normalizing PYD/investment gains than deteriorating fundamentals.
Two things stand out. First, management explicitly warned on the Q1 call that the Iran conflict (political violence / war / terror lines out of London) would generate additional man-made cat losses in Q2, having taken only a "first stab" in Q1. They sized the potential market loss at ~$3B against ~$2B of relevant premium. Second, the industry read-through is cautionary — Cincinnati Financial reported a Q2 combined ratio above 100% on elevated cat losses. Watch whether Arch's Q2 cat load runs above its seasonal expectation, and how much incremental Iran-related loss flows through.
This is the number. Q1's 82.3% (vs. 81.0% a year earlier) confirmed margin compression is underway. Management framed it as "consistent with a more competitive environment." Key questions: - Is the insurance segment underlying loss ratio still improving (Q1 benefited from benign London attritional losses — a tailwind that may not repeat)? - Does reinsurance hold its sub-80% combined ratio streak (four straight quarters through Q1)?
Q2 captures the important 6/1 (Florida) and 7/1 renewals. Management has been candid: property-cat rates are down double digits, and Arch now manages ~50 cat zones dynamically ("some green, some yellow, some turned red"), with Florida still attractive ("green"). Casualty remains the offset — Arch sees rate above trend and continued adverse industry development in accident years 2021–2024 supporting firm pricing. Listen for: net premium trajectory, whether the cat book shrank further at mid-year, and any change in the cat load / PML.
Expect continued NPW pressure. In Q1, consolidated NPW fell 3.7% (reinsurance −6%, insurance −1.4%). Two known drags persist: the ~$250M full-year 2026 headwind from non-renewing MCE (Allianz MidCorp) program business, and reduced property-cat writings. The bull case is that this is deliberate cycle management — declining sub-threshold business while leaning into E&S casualty, construction, alternative markets, and London specialty.
Arch completed the data/system migration of the acquired Allianz MidCorp/Entertainment business onto its own platform in ~18 months (a notable AI-accelerated milestone). Management guided that the operating expense ratio should revert toward historical levels in H2 2026 as transition costs roll off. Watch for early evidence of that in Q2, plus any commentary on scaling this "less-cyclical" SME book (management flagged it as more of a 2027 growth story).
With limited organic growth opportunities across all three segments, buybacks are the release valve. The Board added $3B to the repurchase authorization, and management said on the Q1 call there is "no structural limitation" to buying back up to 100% of income. After $783M in Q1 (a step-up from ~$163M in the year-ago quarter) plus $311M early in Q2, watch the pace — a continued elevated buyback would support EPS/BVPS growth and signal management sees the stock as attractive versus deploying into a soft market.
MI keeps posting ~20%+ underwriting-income quarters (Q1: $221M) with heavy favorable development from strong cure rates. Watch delinquency trends (Q1 U.S. MI delinquency 2.06%, normalizing seasonally) and note that loss ratios may tick up modestly as more recent, larger-balance post-COVID vintages roll into default.
David Gansberg (Global Mortgage Group CEO) filed intent to sell ~$7.6M of stock on 7/20. Routine in size, but worth noting given timing ahead of the print.
The debate isn't about Arch's quality — it's about how gracefully it manages the down-cycle. A "good" Q2 looks like: contained cat losses (including Iran), an underlying combined ratio holding in the low-80s%, disciplined premium shrinkage rather than chasing soft pricing, continued aggressive buybacks, and early expense-ratio normalization. The risks skew toward (a) a heavier-than-expected cat/Iran quarter, (b) faster underlying margin erosion as the soft market bites, and (c) a tough YoY optics comparison against an exceptional Q2 2025. With the stock near highs at ~1.6x book, the market is priced for continued execution — leaving asymmetric downside if margins or cats disappoint, and modest upside if Arch again demonstrates its cycle-management edge.
Note: All figures above are drawn from Arch's Q1 2026 and Q2 2025 earnings releases and the Q1 2026 earnings call; consensus estimates were not available in the sources reviewed, so no formal beat/miss benchmark is provided here.